Ascendis Pharma AS Company Profile (NASDAQ:ASND)

About Ascendis Pharma AS

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ASND
CUSIP:

Key Metrics:

Previous Close: $20.66
50 Day Moving Average: $18.70
200 Day Moving Average: $16.10
52-Week Range: $11.92 - $21.70
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -8.79
P/E Growth: -0.26
Market Cap: $506.13M
Outstanding Shares: 25,193,000
Beta: 0.09

Additional Links:

Companies Related to Ascendis Pharma AS:

Consensus Ratings for Ascendis Pharma AS (NASDAQ:ASND) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$29.00 (42.79% upside)

Analysts' Ratings History for Ascendis Pharma AS (NASDAQ:ASND)

Show:

Date	Firm	Action	Rating	Price Target
9/26/2016	Wedbush	Initiated Coverage	Outperform	$34.00
9/2/2016	Leerink Swann	Reiterated Rating	Buy
2/23/2015	Bank of America Corp.	Initiated Coverage	Buy
2/23/2015	Wells Fargo & Co.	Initiated Coverage	Outperform	$26.00

(Data available from 9/29/2014 forward)

Earnings History for Ascendis Pharma AS (NASDAQ:ASND)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Release Link	Conference Call
11/10/2016
8/31/2016	Q216	($0.69)	($0.59)	$1.11 million	View	Listen
5/20/2016	Q1	($0.55)	($0.92)		View	N/A
11/12/2015	Q315	($0.57)	($0.32)		View	N/A
8/24/2015	Q2	($0.48)	($0.73)		View	N/A
5/18/2015	Q115	($0.37)	$0.07	$2.24 million	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Ascendis Pharma AS (NASDAQ:ASND)

Current Year EPS Consensus Estimate: $-3.14 EPS
Next Year EPS Consensus Estimate: $-2.31 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.55)	($0.55)	($0.55)
Q2 2016	1	($0.77)	($0.77)	($0.77)
Q3 2016	2	($0.87)	($0.66)	($0.77)
Q4 2016	2	($0.89)	($0.66)	($0.78)

(Data provided by Zacks Investment Research)

Dividend History for Ascendis Pharma AS (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ascendis Pharma AS (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Ascendis Pharma AS (NASDAQ:ASND)

Date	Headline
	European ADRs Edge Lower as Telecommunication Stocks See Mixed Fortunes (NASDAQ:ASND) www.nasdaq.com - September 27 at 3:36 PM
	European ADRs Edge Lower as Banks Retreat (NASDAQ:ASND) www.nasdaq.com - September 26 at 3:43 PM
	Wedbush Starts Ascendis Pharma (ASND) at Outperform (NASDAQ:ASND) www.streetinsider.com - September 26 at 3:43 PM
	Coverage initiated on Ascendis Pharma by Wedbush (NASDAQ:ASND) finance.yahoo.com - September 26 at 3:43 PM
	Ascendis Pharma A/S (ASND): Moving Average Crossover Alert (NASDAQ:ASND) finance.yahoo.com - September 26 at 3:43 PM
	Ascendis Pharma A/S Announces Webcast of R&D Update (NASDAQ:ASND) www.publicnow.com - September 23 at 8:30 AM
	Ascendis Pharma A/S Announces Participation in 2016 Morgan Stanley Global Healthcare Conference on September 14 (NASDAQ:ASND) finance.yahoo.com - September 13 at 8:27 AM
	Ascendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting (NASDAQ:ASND) finance.yahoo.com - September 9 at 8:25 AM
	BRIEF-Ascendis Pharma reports Q2 loss per share EUR 0.53 (NASDAQ:ASND) www.reuters.com - September 1 at 12:03 PM
	Ascendis Pharma A/S Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ASND) www.publicnow.com - September 1 at 12:03 PM
	Q2 2016 Ascendis Pharma A/S Earnings Release - After Market Close (NASDAQ:ASND) biz.yahoo.com - August 31 at 8:24 AM
	Can the Rally in Ascendis Pharma (ASND) Shares Continue? (NASDAQ:ASND) finance.yahoo.com - August 26 at 11:43 AM
	New Report Available: Ascendis Pharma A/S (ASND) - Financial and Strategic SWOT Analysis Review (NASDAQ:ASND) www.live-pr.com - August 22 at 8:44 PM
	Ascendis Pharma A/S to Report Second Quarter 2016 Financial Results and Host Conference Call on August 31 (NASDAQ:ASND) www.publicnow.com - August 19 at 11:59 AM
	Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director (NASDAQ:ASND) www.businesswire.com - August 18 at 12:00 PM
	Ascendis Pharma A/S Announces R&D Update to Review Expanded Pipeline and Long-term Strategic Outlook (NASDAQ:ASND) finance.yahoo.com - August 15 at 9:08 PM
	Ascendis Pharma begins phase 3 study of transcon growth hormone in children with GHD (NASDAQ:ASND) www.pharmabiz.com - August 13 at 11:48 AM
	Ascendis Pharma commences late-stage study supporting lead product candidate (NASDAQ:ASND) seekingalpha.com - August 12 at 12:11 PM
	Ascendis Pharma starts phase 3 pediatric GHD study (NASDAQ:ASND) www.bioportfolio.com - August 12 at 12:11 PM
	Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth ... (NASDAQ:ASND) www.prnewswire.com - August 12 at 12:11 PM
	Ascendis Pharma (ASND) Initiates Phase 3 Trial for TransCon Growth Hormone in Children with GHD (NASDAQ:ASND) www.streetinsider.com - August 12 at 12:11 PM
	Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency (NASDAQ:ASND) www.publicnow.com - August 11 at 12:51 PM
	Ascendis Pharma appoints Scott T. Smith as CFO (NASDAQ:ASND) www.poandpo.com - August 9 at 10:12 PM
	Ascendis Pharma (ASND) Names New CFO (NASDAQ:ASND) www.streetinsider.com - August 8 at 3:39 PM
	Ascendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer (NASDAQ:ASND) www.publicnow.com - August 8 at 8:24 AM
	Market Report, "Prostaglandin E2 Receptor EP2 Subtype - Pipeline Review, H1 2016", Published (NASDAQ:ASND) www.sbwire.com - July 13 at 11:44 AM
	Ascendis Pharma (ASND): OrbiMed Advisors Adds More Shares (NASDAQ:ASND) www.insidermonkey.com - July 5 at 8:23 AM
	OrbiMed Advisors Buys Some More Ascendis Pharma (ASND) Shares (NASDAQ:ASND) www.insidermonkey.com - June 26 at 1:59 PM
	Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 (NASDAQ:ASND) www.capitalcube.com - May 26 at 11:15 AM
	Ascendis Pharma A/S Reports First Quarter 2016 Financial Results (NASDAQ:ASND) www.publicnow.com - May 19 at 4:52 PM
	9:04 am Ascendis Pharma appointed Jonathan Leff, M.D. as Chief Medical Officer (NASDAQ:ASND) finance.yahoo.com - February 25 at 9:04 AM
	Ascendis Pharma A/S Appoints Jonathan A. Leff, M.D. as Chief Medical Officer (NASDAQ:ASND) finance.yahoo.com - February 25 at 9:00 AM
	Ascendis Pharma A/S to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:ASND) finance.yahoo.com - February 3 at 5:00 PM
	Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Jacob Gottlieb Adds To Position In Ascendis Pharma A/S (ASND); Armistice Capital Increases Stake In Demand Media Inc (DMD) (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S Earnings Q2, 2015 (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Two Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	How Do Hedge Funds Feel About AK Steel Holding Corporation (AKS)? (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	Ascendis Pharma A/S Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:ASND) us.rd.yahoo.com - January 14 at 11:25 AM
	ASCENDIS PHARMA A/S Financials (NASDAQ:ASND) finance.yahoo.com - December 8 at 1:08 PM
	Ascendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference (NASDAQ:ASND) finance.yahoo.com - November 11 at 4:05 PM
	Ausnutria Dairy Corporation Ltd 2015 Interim Gross Profit and Gross Profit Margin Increased by Approximately 7.3% and 3.0% Points Respectively (NASDAQ:ASND) finance.yahoo.com - August 26 at 3:54 AM
	Will OmniVision's (OVTI) Earnings Surprise Estimates in Q1? (NASDAQ:ASND) finance.yahoo.com - August 25 at 9:20 AM